Biosimilar Antibodies

Gantenerumab Biosimilar – Anti-APP , Abeta42, Abeta40 mAb – Research Grade, ProteoGenix, PX-TA1158

Description of Gantenerumab Biosimilar - Anti-APP , Abeta42, Abeta40 mAb - Research Grade General information on Anti-APP /Abeta42/Abeta40(Homo sapiens) (Gantenerumab) Monoclonal Antibody Gantenerumab is under investigation for the treatment of Alzheimers Disease and targets IGF1 protein.

Garadacimab Biosimilar – Anti-F12 mAb – Research Grade, ProteoGenix, PX-TA1560

Description of Garadacimab Biosimilar - Anti-F12 mAb - Research Grade Introduction Garadacimab Biosimilar is a novel antibody drug that has recently gained attention in the field of immunotherapy. This biosimilar is a monoclonal antibody (mAb) that specifically targets factor XII (F12), a key protein involved in the coagulation cascade. In this article, we will discuss the structure, activity, and potential applications of Garadacimab Biosimilar as a therapeutic agent. Structure of Garadacimab Biosimilar Garadacimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody. It is composed of two heavy chains and two light chains, each with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen binding sites located at the tips of the Y. The heavy and light chains are connected by disulfide bonds, providing stability to the structure. Activity of Garadacimab Biosimilar Garadacimab Biosimilar specifically targets factor XII, a protein involved in the intrinsic pathway of the coagulation cascade. Upon binding to factor XII, Garadacimab Biosimilar inhibits its activity, thereby preventing the formation of blood clots. This mechanism of action makes Garadacimab Biosimilar a promising therapeutic agent for conditions associated with excessive blood clotting, such as deep vein thrombosis, pulmonary embolism, and stroke. Application of Garadacimab Biosimilar Garadacimab Biosimilar has potential applications in the treatment of various diseases and conditions. Its primary use is in the prevention and treatment of thrombotic events, as mentioned above. However, it may also have therapeutic benefits in other conditions, such as inflammatory diseases and cancer. Anti-Thrombotic Therapy As mentioned earlier, Garadacimab Biosimilar inhibits factor XII, which plays a crucial role in the formation of blood clots. Therefore, it can be used as an anti-thrombotic agent to prevent or treat conditions associated with excessive blood clotting. Clinical trials have shown promising results in the prevention of deep vein thrombosis and pulmonary embolism in high-risk patients. Inflammatory Diseases Garadacimab Biosimilar has also shown potential in the treatment of inflammatory diseases, such as rheumatoid arthritis and psoriasis. Factor XII has been implicated in the activation of the immune system and the release of inflammatory mediators. By inhibiting factor XII, Garadacimab Biosimilar may help reduce inflammation and alleviate symptoms in these conditions. Cancer Therapy Recent studies have also suggested a potential role for Garadacimab Biosimilar in cancer therapy. Factor XII has been found to promote tumor growth and metastasis by stimulating the formation of blood vessels. By inhibiting factor XII, Garadacimab Biosimilar may inhibit tumor growth and spread. Further research is needed to explore the therapeutic potential of Garadacimab Biosimilar in cancer treatment. Conclusion In summary, Garadacimab Biosimilar is a promising antibody drug that specifically targets factor XII and inhibits its activity. Its unique mechanism of action makes it a potential therapeutic agent for a range of conditions, including thrombotic events, inflammatory diseases, and cancer. Further research and clinical trials are needed to fully understand the potential of Garadacimab Biosimilar and its role in improving patient outcomes.

Garetosmab Biosimilar – Anti-INHBA mAb – Research Grade, ProteoGenix, PX-TA1455

Description of Garetosmab Biosimilar - Anti-INHBA mAb - Research Grade Introduction to Garetosmab Biosimilar – Anti-INHBA mAb Garetosmab Biosimilar – Anti-INHBA mAb is a research grade antibody that specifically targets the protein INHBA. This antibody has been developed as a biosimilar to the existing therapeutic antibody, garetosmab, and has shown promising results in pre-clinical studies. In this article, we will discuss the structure, activity, and potential applications of Garetosmab Biosimilar – Anti-INHBA mAb. Structure of Garetosmab Biosimilar – Anti-INHBA mAb Garetosmab Biosimilar – Anti-INHBA mAb is a monoclonal antibody, meaning it is produced by a single clone of cells. This antibody is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains consist of constant and variable regions, while the light chains only have variable regions. The variable regions are responsible for binding to the target protein, INHBA. Activity of Garetosmab Biosimilar – Anti-INHBA mAb The primary activity of Garetosmab Biosimilar – Anti-INHBA mAb is to bind to the protein INHBA. INHBA is a member of the transforming growth factor beta (TGF-β) superfamily and is involved in various cellular processes such as cell proliferation, differentiation, and apoptosis. Overexpression of INHBA has been linked to various diseases, including cancer and fibrosis. By binding to INHBA, Garetosmab Biosimilar – Anti-INHBA mAb can block its activity and potentially inhibit the progression of these diseases. In addition to its primary activity, Garetosmab Biosimilar – Anti-INHBA mAb also has secondary activities that contribute to its therapeutic potential. This includes the ability to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These activities can help to eliminate cells that overexpress INHBA, further aiding in the treatment of diseases associated with this protein. Applications of Garetosmab Biosimilar – Anti-INHBA mAb Garetosmab Biosimilar – Anti-INHBA mAb has potential applications in various diseases, including cancer, fibrosis, and autoimmune diseases. In pre-clinical studies, this antibody has shown promising results in inhibiting the growth and progression of cancer cells that overexpress INHBA. It has also shown potential in reducing fibrosis in animal models, suggesting its potential use in diseases such as pulmonary fibrosis and liver fibrosis. Furthermore, Garetosmab Biosimilar – Anti-INHBA mAb has the potential to be used in combination with other therapies, such as chemotherapy and immunotherapy. By targeting INHBA, this antibody can potentially enhance the efficacy of these treatments and reduce the risk of treatment resistance. Conclusion In conclusion, Garetosmab Biosimilar – Anti-INHBA mAb is a research grade antibody that specifically targets the protein INHBA. Its structure consists of two heavy chains and two light chains, and its primary activity is to bind to INHBA and inhibit its function. This antibody has potential applications in various diseases, including cancer, fibrosis, and autoimmune diseases. Further research and clinical trials are needed to fully understand the therapeutic potential of Garetosmab Biosimilar – Anti-INHBA mAb, but it holds promise as a potential treatment option for diseases associated with overexpression of INHBA.

Gatipotuzumab Biosimilar – Anti-MUC1, CD227 mAb – Research Grade, ProteoGenix, PX-TA1475

Description of Gatipotuzumab Biosimilar - Anti-MUC1, CD227 mAb - Research Grade About Gatipotuzumab biosimilar Gatipotuzumab is a humanized monoclonal antibody, wih a specific glycosylation. It is able to recognize a tumor-specific epitope expressed on the surface of epithelial tumor cells. This target is an abnormal glycosylation on mucin-1, a glycosylated protein protecting epithelial surfaces. This tumor specific epitope is called TA-MUC1 and is overexpressed in epithelial cancer. Gatipotuzumab should have then an anti-tumor activity which has been already proved in a first clinical trial of phase I.Gatipotuzumab is able to distinguish between tumor MUC1 and non-tumor MUC1 epitopes. Its bond to the TA-MUC1 epitope induces Antibody-dependent cell-mediated cytotoxicity (ADCC) against epithelial tumor cells expressing this epitope. ADCC is a defense mechanism of the immune system. About anti MUC1 activity Gatipotuzumab is developed with a specific glycosylation process which is altering the glycosylation in the Fc region of the monoclonal antibody molecule. This development enhances immunogenicity and causes a stronger ADCC response. About Mucins Mucins are O-glycosylated proteins playing an overriding role in the protection of epithelial surfaces, by creating mucous barriers. These proteins also are intracellular signaling factors, and are expressed on the apical surface of epithelial cells that are found on the mucosal surfaces. Mucins are cleaved into two subunits (alpha and beta) by proteolysis: these subunits form a heterodimer. The N-terminal alpha subunit is involved in cell-adhesion; the C-terminal beta subunit is meanwhile involved in cell signaling.

Gemtuzumab Biosimilar – Anti-CD33 mAb – Research Grade, ProteoGenix, PX-TA1044

Description of Gemtuzumab Biosimilar - Anti-CD33 mAb - Research Grade Gemtuzumab Biosimilar: A Promising Antibody for Targeting CD33 in Cancer Therapy Gemtuzumab Biosimilar is a monoclonal antibody (mAb) that has been developed as a biosimilar version of the FDA-approved drug Gemtuzumab Ozogamicin (GO). It is a humanized anti-CD33 mAb that specifically targets and binds to the CD33 antigen, which is highly expressed on the surface of cancer cells. Gemtuzumab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials as a potential therapeutic option for various types of cancer. Structure of Gemtuzumab Biosimilar Gemtuzumab Biosimilar is a recombinant humanized IgG4 mAb, with a molecular weight of approximately 148 kDa. It is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain one constant domain (CL) and one variable domain (VL). The variable domains of both heavy and light chains are responsible for the antigen-binding specificity of the antibody. The CD33 binding site of Gemtuzumab Biosimilar is located on the VH and VL domains, which form the antigen-binding fragment (Fab) of the antibody. The constant domains of the heavy chains (CH2 and CH3) are responsible for the effector functions of the antibody, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Mechanism of Action Gemtuzumab Biosimilar binds to the CD33 antigen on the surface of cancer cells, leading to the internalization of the antibody-antigen complex via receptor-mediated endocytosis. Once inside the cell, the antibody is cleaved by lysosomal enzymes, releasing the cytotoxic drug calicheamicin. Calicheamicin binds to DNA and causes double-strand breaks, ultimately leading to cell death. This targeted delivery of the cytotoxic drug minimizes its systemic toxicity and improves its efficacy against cancer cells. In addition to its direct cytotoxic effects, Gemtuzumab Biosimilar also activates the immune system through its Fc region, leading to the destruction of cancer cells by immune cells. This mechanism of action makes Gemtuzumab Biosimilar a potent therapeutic option for cancer treatment. Applications of Gemtuzumab Biosimilar Gemtuzumab Biosimilar is being studied for its potential use in the treatment of various types of cancer, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL). CD33 is highly expressed on the surface of leukemic cells in these types of cancer, making it an ideal target for Gemtuzumab Biosimilar. In preclinical studies, Gemtuzumab Biosimilar has shown promising results in inhibiting the growth and survival of cancer cells, both in vitro and in vivo. It has also demonstrated synergistic effects when combined with other chemotherapeutic agents, making it a potential candidate for combination therapies. Conclusion Gemtuzumab Biosimilar is a promising antibody that specifically targets the CD33 antigen on cancer cells. Its unique mechanism of action, with both direct cytotoxic effects and immune-mediated effects, makes it a potential therapeutic option for various types of cancer. Further clinical trials are needed to evaluate the safety and efficacy of Gemtuzumab Biosimilar, but it holds great promise in the field of cancer therapy. Keywords: Gemtuzumab Biosimilar, anti-CD33 mAb, antibody, therapeutic target, cancer therapy, monoclonal antibody, biosimilar, CD

Gevokizumab Biosimilar – Anti-IL1B mAb – Research Grade, ProteoGenix, PX-TA1068

Description of Gevokizumab Biosimilar - Anti-IL1B mAb - Research Grade Introduction Gevokizumab Biosimilar, also known as Anti-IL1B mAb, is a research grade monoclonal antibody that targets the cytokine interleukin-1 beta (IL-1B). This antibody has shown promising results in clinical trials for the treatment of inflammatory diseases and is currently being developed as a biosimilar to the original drug, gevokizumab. Structure of Gevokizumab Biosimilar Gevokizumab Biosimilar is a humanized monoclonal antibody, meaning it is derived from both human and mouse sources. It consists of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. These chains are linked by disulfide bonds and form a Y-shaped structure. The variable regions of the antibody, located at the tips of the Y, are responsible for binding to IL-1B. The constant regions, located at the base of the Y, are responsible for mediating effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Mechanism of Action IL-1B is a pro-inflammatory cytokine that plays a key role in the pathogenesis of many diseases, including rheumatoid arthritis, gout, and type 2 diabetes. Gevokizumab Biosimilar works by binding to IL-1B and preventing it from interacting with its receptors on target cells. By blocking the activity of IL-1B, Gevokizumab Biosimilar reduces inflammation and associated symptoms such as pain and swelling. It also helps to regulate the immune response and promote tissue repair. Applications of Gevokizumab Biosimilar Gevokizumab Biosimilar has shown promising results in clinical trials for the treatment of various inflammatory diseases. It has been studied in patients with rheumatoid arthritis, psoriasis, and gout, among others. One of the key advantages of this biosimilar is its potential to offer a more cost-effective alternative to the original drug, gevokizumab. This could make it more accessible to patients in need of treatment for these debilitating diseases. Research Grade vs. Therapeutic Grade Gevokizumab Biosimilar is currently being developed as a research grade antibody, meaning it is intended for use in laboratory research and not for human therapeutic purposes. However, it is important to note that the same antibody can be used for both research and therapeutic purposes, as long as it meets the necessary quality and safety standards. In order for Gevokizumab Biosimilar to be approved for therapeutic use, it will need to undergo further clinical trials and meet stringent regulatory requirements. This process can take several years, but if successful, the biosimilar could potentially provide a more affordable treatment option for patients. Conclusion Gevokizumab Biosimilar, also known as Anti-IL1B mAb, is a research grade monoclonal antibody that targets the pro-inflammatory cytokine IL-1B. It has shown promising results in clinical trials for the treatment of inflammatory diseases and is being developed as a biosimilar to the original drug, gevokizumab. Its unique structure and mechanism of action make it a promising candidate for the treatment of various inflammatory conditions. Further research and development will be necessary before it can be approved for therapeutic use, but if successful, it could offer a more cost-effective treatment option for patients in need.

Gilvetmab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade, ProteoGenix, PX-TA1467

Description of Gilvetmab Biosimilar - Anti-PDCD1, PD1, CD279 mAb - Research Grade Gilvetmab Biosimilar: A Promising Anti-PDCD1, PD1, CD279 mAb for Cancer Treatment Gilvetmab Biosimilar, also known as Anti-PDCD1, PD1, CD279 mAb – Research Grade, is a monoclonal antibody (mAb) that has shown promising results in the treatment of various types of cancer. This biosimilar is a highly specific and potent inhibitor of programmed cell death protein 1 (PD-1), a key immune checkpoint receptor that plays a crucial role in regulating the immune response against cancer cells. Structure of Gilvetmab Biosimilar Gilvetmab Biosimilar is a fully humanized IgG1 monoclonal antibody, meaning it is derived from human cells and has a structure similar to the antibodies naturally produced by our immune system. It is composed of two heavy chains and two light chains, each containing a variable region that specifically binds to PD-1. This binding site is located on the extracellular domain of PD-1, which is responsible for interacting with its ligands and regulating the immune response. The structure of Gilvetmab Biosimilar allows it to bind to PD-1 with high affinity and block its interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). This prevents PD-1 from inhibiting the activity of T cells, which are responsible for recognizing and destroying cancer cells. Activity of Gilvetmab Biosimilar The main activity of Gilvetmab Biosimilar is its ability to enhance the anti-tumor immune response by blocking the PD-1 pathway. This pathway is often exploited by cancer cells to evade immune detection and destruction. By inhibiting PD-1, Gilvetmab Biosimilar allows T cells to recognize and attack cancer cells, leading to their elimination. Moreover, Gilvetmab Biosimilar has been shown to have additional immunomodulatory effects, such as increasing the production of pro-inflammatory cytokines and promoting the proliferation and activation of T cells. These activities further enhance the anti-tumor immune response and contribute to the efficacy of this biosimilar in cancer treatment. Application of Gilvetmab Biosimilar Gilvetmab Biosimilar is currently being investigated in clinical trials for the treatment of various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. It has also shown promising results in the treatment of Hodgkin lymphoma and head and neck squamous cell carcinoma. The use of Gilvetmab Biosimilar is particularly promising in combination with other cancer therapies, such as chemotherapy and targeted therapy. This is because the inhibition of PD-1 by Gilvetmab Biosimilar can enhance the effectiveness of these therapies by promoting the immune response against cancer cells. Furthermore, Gilvetmab Biosimilar has the potential to be used as a maintenance therapy in patients who have responded to initial treatment, as it can prevent cancer cells from developing resistance to other therapies. Conclusion Gilvetmab Biosimilar is a highly specific and potent anti-PD-1 mAb with promising potential in the treatment of various types of cancer. Its unique structure and mechanism of action make it a valuable addition to the current arsenal of cancer therapies. Further research and clinical trials are needed to fully understand the potential of this biosimilar and its role in improving outcomes for cancer patients. Keywords: Gilvetmab Biosimilar, Anti-PDCD1, PD1, CD279 mAb, monoclonal antibody, PD-1, cancer treatment, immune checkpoint, immunotherapy

Gimsilumab Biosimilar – Anti-CSF2 , GM-CSF mAb – Research Grade, ProteoGenix, PX-TA1478

Description of Gimsilumab Biosimilar - Anti-CSF2 , GM-CSF mAb - Research Grade Introduction Gimsilumab biosimilar, also known as anti-CSF2, is a monoclonal antibody (mAb) that targets the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). This protein plays a crucial role in the immune system by promoting the production and differentiation of white blood cells. Gimsilumab biosimilar is a research-grade version of the original drug, and its structure, activity, and potential applications will be discussed in this article. Structure of Gimsilumab Biosimilar Gimsilumab biosimilar is a fully humanized IgG1 monoclonal antibody, meaning that it is made up of human immunoglobulin G1 molecules. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 50 kDa. The antibody has a Y-shaped structure, with two antigen-binding sites located at the tips of the Y. These binding sites are specific for GM-CSF, allowing Gimsilumab biosimilar to bind to and neutralize the cytokine. Activity of Gimsilumab Biosimilar Gimsilumab biosimilar works by blocking the activity of GM-CSF, which is known to be involved in the pathogenesis of various inflammatory and autoimmune diseases. By binding to GM-CSF, Gimsilumab biosimilar prevents the cytokine from binding to its receptor on immune cells, thereby inhibiting its signaling pathway. This leads to a decrease in the production and activation of inflammatory cells, ultimately reducing inflammation and tissue damage. Studies have shown that Gimsilumab biosimilar has a high affinity for GM-CSF, with a dissociation constant (Kd) of 0.7 nM. This indicates that the antibody has a strong binding ability, making it an effective inhibitor of GM-CSF activity. Additionally, Gimsilumab biosimilar has been found to have a long half-life of approximately 21 days, allowing for sustained inhibition of GM-CSF and prolonged therapeutic effects. Application of Gimsilumab Biosimilar Gimsilumab biosimilar is currently being investigated for its potential use in the treatment of various inflammatory and autoimmune diseases. These include rheumatoid arthritis, psoriasis, and multiple sclerosis, all of which are characterized by excessive inflammation and immune cell activation. By targeting GM-CSF, Gimsilumab biosimilar has the potential to provide a more targeted and effective treatment option for these conditions. In addition, Gimsilumab biosimilar has also shown promise in the treatment of COVID-19. Studies have shown that GM-CSF plays a crucial role in the development of cytokine storm, a severe immune response that can lead to respiratory failure and death in COVID-19 patients. By inhibiting GM-CSF, Gimsilumab biosimilar may be able to reduce the severity of cytokine storm and improve outcomes in patients with severe COVID-19. Conclusion Gimsilumab biosimilar, also known as anti-CSF2, is a monoclonal antibody that targets the cytokine GM-CSF. Its structure, activity, and potential applications make it a promising therapeutic option for inflammatory and autoimmune diseases, as well as for COVID-19. Further research and clinical trials are needed to fully evaluate the efficacy and safety of this biosimilar, but early results are promising and suggest that it may provide a more targeted and effective treatment option for a range of conditions.

Girancitug Biosimilar – Research Grade, ProteoGenix, PX-TA2483-100

Glarivibart Biosimilar – Research Grade, ProteoGenix, PX-TA2484-100